We are live on ! Find out more
EIGR

Eiger BioPharmaceuticals, Inc.
EIGR

Delisted

EIGR was delisted on the 10th of April, 2024.

Back to rankings

30 hedge funds and large institutions have $51.1M invested in Eiger BioPharmaceuticals, Inc. in 2016 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

348% more capital invested

Capital invested by funds: $11.4M → $51.1M (+$39.7M)

42.66% more ownership

Funds ownership: 0% → 42.66% (+43%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

27% less funds holding

Funds holding: 41 → 30 (-11)

50% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 20

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $47K

Holders
30
Holders Change
-11
Holders Change %
-26.83%
% of All Funds
0.8%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
10
Increased
5
Reduced
5
Closed
20
Calls
–
Puts
$47K
Net Calls
-$47K
Net Calls Change
-$43K

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$4.84M
2
SM
Sabby Management
Florida
+$4.31M
3
SFM
Sphera Funds Management
Israel
+$2.45M
4
PA
Perceptive Advisors
New York
+$1.74M
5
LOAMU
Lombard Odier Asset Management (USA)
New York
+$698K

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Advisers
Two Sigma Advisers
New York
-$142K
2
Two Sigma Investments
Two Sigma Investments
New York
-$125K
3
Citadel Advisors
Citadel Advisors
Florida
-$111K
4
Millennium Management
Millennium Management
New York
-$103K
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$91K

EIGR Hedge Fund Activity: Q1 2016 in Review

30 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q1 2016, worth a combined $51.1M — up 348% from $11.4M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of EIGR and 10 opened new positions — a net loss of 10 holders — while 5 trimmed existing stakes and 5 added.

The largest buyer was RA Capital Management, opening a new position worth an estimated $4.84M. The largest seller was Two Sigma Advisers, exiting entirely with an estimated $142K sold.

  • 30 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q1 2016, down from 41 in Q4 2015.
  • Funds reported $51.1M of Eiger BioPharmaceuticals, Inc. stock for Q1 2016, up 348% quarter-over-quarter.
  • 10 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q1 2016 and 20 closed out, a net change of -10 holders.
  • The largest Eiger BioPharmaceuticals, Inc. buyer in Q1 2016 was RA Capital Management, an estimated $4.84M added.
  • The largest Eiger BioPharmaceuticals, Inc. seller in Q1 2016 was Two Sigma Advisers, an estimated $142K sold.

Based on aggregated 13F filings for Q1 2016.